BRUKER CORP (BRKR): Results of Operations and Financial Condition
BRUKER CORP (BRKR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bruker Reports Second Quarter 2026 Financial Results • Q2-26 Bruker Scientific Instruments (BSI) bookings up 10% organically year-over-year (yoy), with BSI book-to-bill >1.0x • Q2-26 revenue of $838.5 million, up +5.2% yoy; up 2.8% organically, or +3.4% excluding tar
How this was made
The 30-second read
Why it matters
Traders can update models using the new Q2 datapoints and the revised FY2026 revenue and non-GAAP EPS ranges, while noting management’s guidance change is limited to currency and tax.
Market read
The filing provides fresh quarterly performance and a specific FY2026 non-GAAP EPS range ($2.10 to $2.15), supporting near-term positioning in BRKR.
What to watch
GAAP results include $134.9M non-cash goodwill impairment charges, which can keep longer-term risk perception elevated even if non-GAAP profitability improves.
Q2-26 revenue of $838.5 million, up +5.2% yoy; GAAP diluted loss per share of $(0.41) and non-GAAP diluted EPS of $0.49.
Revenue returned to organic growth and non-GAAP operating income, margin and EPS improved, but GAAP results were affected by $134.9 million of non-cash goodwill impairment charges and US academic demand remained soft.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, Q2-26GAAP | $838.5 million | – | 5.2% |
| Organic revenue growth, Q2-26other | 2.8% | – | – |
| Organic revenue growth excluding tariff refunds, Q2-26other | 3.4% | – | – |
| Growth from acquisitions, Q2-26other | 1.5% | – | – |
| Constant-exchange rate revenue growth, Q2-26other | 4.3% | – | – |
| Foreign currency translation impact, Q2-26other | 0.9% | – | – |
| GAAP operating loss, Q2-26GAAP | $(65.3) million | – | – |
| Non-GAAP operating income, Q2-26non-GAAP | $118.5 million | – | – |
| Non-GAAP operating margin, Q2-26non-GAAP | 14.1% | – | – |
| GAAP diluted loss per share, Q2-26GAAP | $(0.41) | – | – |
| Non-GAAP diluted EPS, Q2-26non-GAAP | $0.49 | – | – |
| Total revenue, first half of 2026GAAP | $1.7 billion | – | 3.9% |
| Organic revenue growth, first half of 2026other | (0.8%) | – | – |
| Growth from acquisitions, first half of 2026other | 2.0% | – | – |
| Constant-exchange rate revenue growth, first half of 2026other | 1.2% | – | – |
| Foreign currency translation impact, first half of 2026other | 2.7% | – | – |
| GAAP operating loss, first half of 2026GAAP | $(55.1) million | – | – |
| Non-GAAP operating income, first half of 2026non-GAAP | $202.7 million | – | – |
| Non-GAAP operating margin, first half of 2026non-GAAP | 12.2% | – | – |
| GAAP diluted loss per share, first half of 2026GAAP | $(0.39) | – | – |
| Non-GAAP diluted EPS, first half of 2026non-GAAP | $0.80 | – | – |
| Non-cash goodwill impairment charges, Q2-26GAAP | $134.9 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Bruker Scientific Instruments (BSI), Q2-26Organic revenue increased by 2.3%; bookings were up 10% organically year-over-year and book-to-bill was >1.0x. | $767.3 million | – | 4.7% |
| Bruker Energy & Supercon Technologies (BEST), Q2-26Organic revenue increased by 8.9%, net of intercompany eliminations. | $74.2 million | – | 11.9% |
| Bruker Scientific Instruments (BSI), first half of 2026Revenue decreased by 1.4% organically. | $1.5 billion | – | 3.3% |
| Bruker Energy & Supercon Technologies (BEST), first half of 2026Organic growth was 6.1%, net of intercompany eliminations. | $141.0 million | – | 12.3% |
FY26 outlook
- Revenue$3.54 to $3.57 billion
- Tax rate27.5%
- Note3% to 4% year-over-year reported revenue growth
- NoteOrganic revenue growth of 1% to 2%
- NoteM&A revenue growth of approximately 1.5%
- NoteCER revenue growth of 2.5% to 3.5%
- NoteForeign currency translation revenue tailwind of approximately 0.5% (previously 1.5%)
- NoteNon-GAAP EPS of $2.10 to $2.15
- NoteNon-GAAP EPS growth of 15% to 17% year-over-year
- NoteCurrency headwind of approximately $0.10, or 5%
What drove it
- Q2-26 BSI bookings were up 10% organically year-over-year, with BSI book-to-bill >1.0x.
- Bruker cited strong order bookings growth for differentiated products and solutions in semiconductor tools, energy research and biopharma markets.
- Europe and China aca/gov bookings were up strongly.
- Q2-26 reported revenue growth included 1.5% growth from acquisitions and a favorable 0.9% foreign currency translation impact.
- Management cited a focus on cost and profitability and reported non-GAAP operating-margin expansion.
Concerns
- US academic demand remained soft in Q2.
- First-half revenue decreased organically by 0.8% year-over-year.
- Q2-26 GAAP operating loss included non-cash goodwill impairment charges of $134.9 million.
- FY26 foreign currency translation revenue tailwind is approximately 0.5%, previously 1.5%.
- FY26 non-GAAP EPS includes a currency headwind of approximately $0.10, or 5%.
What to watch
- Whether BSI bookings growth and book-to-bill >1.0x translate into sustained revenue growth.
- The trajectory of US academic demand and the stated gradual market recovery.
- Execution toward FY26 organic revenue growth of 1% to 2%.
- Delivery of FY26 non-GAAP EPS of $2.10 to $2.15 at an effective non-GAAP tax rate of 27.5%.
- The extent of organic margin expansion anticipated by management in 2026 and 2027.
Analysis
Bruker reported Q2-26 revenue of $838.5 million, up 5.2% year-over-year, and returned to organic growth of 2.8%. Organic growth was 3.4% excluding tariff refunds. Reported growth also reflected 1.5% growth from acquisitions and a favorable 0.9% foreign currency translation impact. For the first half, however, organic revenue decreased by 0.8% year-over-year, showing that the Q2 improvement followed a softer first-quarter backdrop.
BSI generated $767.3 million of Q2 revenue, up 4.7% year-over-year, while organic revenue increased 2.3%. The more significant demand indicator was BSI bookings, which increased 10% organically year-over-year, with book-to-bill above 1.0x. BEST grew faster, with revenue of $74.2 million up 11.9% and organic revenue up 8.9%, net of intercompany eliminations. Management identified semiconductor tools, energy research and biopharma as areas of strong order bookings, while US academic demand remained soft.
Profitability improved materially on the non-GAAP basis. Non-GAAP operating income rose to $118.5 million from $72.0 million, and non-GAAP operating margin improved to 14.1% from 9.0%. Non-GAAP diluted EPS increased to $0.49 from $0.32. GAAP operating loss was $(65.3) million and GAAP diluted loss per share was $(0.41), with second-quarter GAAP results including $134.9 million of non-cash goodwill impairment charges.
Bruker updated FY26 guidance for currency and tax only. It expects revenues of $3.54 to $3.57 billion, organic growth of 1% to 2%, and non-GAAP EPS of $2.10 to $2.15. The outlook incorporates an approximately 0.5% foreign currency translation revenue tailwind, previously 1.5%, and a currency headwind of approximately $0.10, or 5%, to non-GAAP EPS. The key reporting priorities are conversion of elevated BSI bookings into revenue, recovery in US academic demand, and continuation of the reported non-GAAP margin expansion.
Management, verbatim
We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year.
Frank H. Laukien, President and CEO
Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter.
Frank H. Laukien, President and CEO
In our academic and medical research business, US academic demand remained soft in Q2, while aca/gov bookings in Europe and China were up strongly.
Frank H. Laukien, President and CEO
Not in the filing
stated, not guessed- Q2-26 GAAP gross profit, gross margin, net income, cash flow from operations, free cash flow, cash balance, debt balance, dividends and share repurchases were not provided in the supplied filing text.
- Q2-26 non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP net income, non-GAAP SG&A expense, non-GAAP interest and other income (expense), net, non-GAAP profit before income taxes and non-GAAP income tax rate were not provided in the supplied filing text.
- FY26 guidance for gross margin and operating expenses was not provided in the supplied filing text.
- Prior-quarter comparisons for reported metrics were not provided in the supplied filing text.
- A previous outlook section was not provided, so comparison of actual results with prior guidance cannot be made.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Bruker’s SEC Form 8-K (Item 2.02) with Q2 2026 results and an FY2026 outlook update.
Ticker impact
Bruker reported Q2 2026 revenue of $838.5M, non-GAAP EPS of $0.49, and updated FY2026 guidance for currency and tax only.
Likely modest positive bias for BRKR as traders price in improved non-GAAP EPS range ($2.10 to $2.15) and margin expansion, with upside capped by the guidance being currency/tax-only.
The filing provides concrete quarterly results (revenue growth, non-GAAP EPS) and a specific FY2026 non-GAAP EPS range increase versus FY25, while stating the revenue and EPS outlook is updated only for currency and tax, reducing the probability of a major fundamental re-rating from this release alone.
Market effects
Scientific instruments and semiconductor tools demand signals (BSI bookings up 10% organically, BSI book-to-bill >1.0) may support sentiment across lab/analytical instrumentation peers.
No explicit regional macro shock; commentary highlights stronger aca/gov bookings in Europe and China versus soft US academic demand.
Currency and tax sensitivity is emphasized, which can matter for multinational instrumentation names with similar FX exposure.
Counterpoint
Because the company says FY2026 guidance is updated for currency and tax only, the market may overreact to the EPS range without a corresponding organic growth acceleration.
Key entities
- companyBruker Corporation
Reported Q2 2026 financial results and updated FY2026 guidance for currency and tax only.
- segmentBruker Scientific Instruments (BSI)
Bookings up 10% organically YoY; BSI book-to-bill >1.0x; Q2 revenue $767.3M.
- segmentBruker Energy & Supercon Technologies (BEST)
Q2 revenue $74.2M, up 11.9% YoY with 8.9% organic growth net of intercompany eliminations.
